All News
Filter News
Found 808,979 articles
-
Biocom California Appoints Bernard Parker as New Vice Chair of Diversity, Equity and Inclusion and Appoints Charles Dadswell as Chairman of Newly Formed Public Policy Advisory Committee
8/24/2021
Biocom California Appoints Bernard Parker as New Vice Chair of Diversity, Equity and Inclusion and Appoints Charles Dadswell as Chairman of Newly Formed Public Policy Advisory Committee
-
Fosun Pharma Announces 2021 Interim Results
8/24/2021
Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH, 02196.HK), a leading healthcare group in China, announced its interim results for the first half of 2021 ("the Reporting Period").
-
FDA Grants Marketing Authorization to Siemens Healthineers ELF Test for NASH Prognostic Assessment
8/24/2021
Siemens Healthineers announced today that its Enhanced Liver Fibrosis (ELF™) Test was granted marketing authorization under the De Novo review pathway.
-
Imbed Biosciences Partners with Spartan Medical to Provide Advanced Surgical and Wound Care Products to U.S. Veterans and Military Members
8/24/2021
Imbed Biosciences announced today that it has signed a distribution agreement with Spartan Medical.
-
Smart Meter Announces Launch of iGlucose Blood Glucose Monitoring (BGM) System for Use in Managing Gestational Diabetes
8/24/2021
Company's cellular-connected blood glucose solution provides remote patient monitoring (RPM) for simplified and improved patient care and support during pregnancy
-
New England Biolabs® Introduces Updated Versions of WarmStart® LAMP Reagents
8/24/2021
New England Biolabs (NEB ® ) announces the release of its newest loop-mediated isothermal amplification (LAMP) products: the WarmStart Multi-Purpose LAMP/RT-LAMP 2X Master Mix
-
Ascletis Announces Completion of the Bridging Study and Initiation of Phase II Trial of FXR Agonist ASC42 in China for Chronic Hepatitis B Indication
8/24/2021
Ascletis Pharma Inc. (HKEX: 1672) announces today the completion of the bridging study and initiation of Phase II trial of farnesoid X receptor (FXR) agonist ASC42 in China for chronic hepatitis B (CHB) indication.
-
Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor
8/24/2021
Pieris Pharmaceuticals, Inc. announced today the presentation of preclinical data for PRS-220, a connective tissue growth factor (CTGF) inhibitor the Company is developing for the treatment of idiopathic pulmonary fibrosis (IPF)
-
GenScript Biotech Reports First Half 2021 Results
8/24/2021
GenScript Biotech Corporation today reported its first half 2021 financial results for the six months ended June 30.
-
Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
8/24/2021
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) , today announced that its SARS-CoV-2 (virus that causes COVID-19) neutralizing monoclonal antibody combination therapy, BRII-196/BRII-198 ("combination BRII-196/BRII-198"),
-
Dr. Craig Bunnell Joins Advisory Board of Cancer Diagnostic and Precision Oncology Platform Developer 4D Path
8/24/2021
4D Path is pleased to announce that Dr. Craig A. Bunnell, MD, MPH, MBA, has joined the company’s distinguished advisory board.
-
Humanetics Corporation’s BIO 300 Receives Fast Track Designation from FDA
8/24/2021
Humanetics Corporation (Humanetics) announced today that BIO 300, a drug under development to increase survival in persons exposed to high levels of radiation, has been granted Fast Track status by the U.S. Food and Drug Administration (FDA).
-
BioAesthetics Announces NIH Grant to Develop NextGen Graft for Burn Survivors
8/24/2021
BioAesthetics Corporation today announced that it has received a Small Business Technology Transfer (STTR) Phase I grant through the National Institute of General Medical Sciences (NIGMS) to further develop its platform technology of enhanced biologically derived grafts
-
Adjuvance Technologies Announces First Clinical Results of its Next-generation Saponin Adjuvant
8/24/2021
Adjuvance Technologies Inc. announced that its adjuvant TQL-1055 was safe and well-tolerated with a co-administered pertussis vaccine.
-
Pharmapack Europe: Innovation, Networking and Education
8/24/2021
Pharmapack 2021 will showcase many of the latest innovations in the industry and bring the entire community together to help foster new advances.
-
Checkpoint Surgical Completes $16M Equity Financing to Fuel Growth and Launch New Products
8/24/2021
Checkpoint Surgical, Inc. announced today the completion of a $16 million capital raise led by River Cities Capital, a Cincinnati-based healthcare-focused growth equity firm.
-
Deepcell Achieves Milestone of 1 Billion Images in Rapidly Expanding Cell Morphology Atlas
8/24/2021
Deepcell today announced that it has surpassed the milestone of 1 billion cell images in its Cell Morphology Atlas.
-
Shape Memory Medical Announces First Patient Enrollment in the AAA-SHAPE Netherlands Study
8/24/2021
Shape Memory Medical Inc., developer of innovative therapies for cardiovascular and neurovascular markets, announced the initiation of AAA-SHAPE Netherlands, the Company’s prospective, multicenter early feasibility study of the IMPEDE-FX RapidFill® Device when used for abdominal aortic aneurysm (AAA) sac management during elective endovascular aneurysm repair (EVAR).
-
DiCE Molecules Announces $60 Million Series C-1 Financing
8/24/2021
DiCE Molecules today announced the completion of its $60 million Series C-1 financing.
-
MedX Announces Board Changes
8/24/2021
MedX Health Corp. (“MedX” or the “Company”) ( MDX – TSXV), announces that at the Annual and Special General Meeting of shareholders held on August 16, 2021, Rob von der Porten retired as a director, thus creating a vacancy on the Board.